Discovery and significance of new human T-lymphotropic viruses: HTLV-3 and HTLV-4

References

• Ohshima K. Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci.98(6), 772–778 (2007).
   PubMed Web of Science ®Google Scholar
• Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene24(39), 6058–6068 (2005).
   PubMed Web of Science ®Google Scholar
• Journo C, Douceron E, Mahieux R. HTLV gene regulation: because size matters, transcription is not enough. Future Microbiol.4(4), 425–440 (2009).
   PubMedGoogle Scholar
• Gallo RC. The discovery of the first human retrovirus: HTLV-1 and HTLV-2. Retrovirology2, 17 (2005).
   PubMed Web of Science ®Google Scholar
• Matsuoka M, Jeang KT. Human T-cell leukemia virus type I at age 25: a progress report. Cancer Res.65(11), 4467–4470 (2005).
   PubMedGoogle Scholar
• Feuer G, Green PL. Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2. Oncogene24(39), 5996–6004 (2005).
   PubMed Web of Science ®Google Scholar
• Prince H, Kleinman S, Doyle M, Lee H, Swanson P. Spontaneous lymphocyte proliferation in vitro characterizes both HTLV-I and HTLV-II infection. J. Acquir. Immune Defic. Syndr.3(12), 1199–1200 (1990).
   PubMedGoogle Scholar
• Bartman MT, Kaidarova Z, Hirschkorn D et al. Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection. Blood112(10), 3995–4002 (2008).
   PubMed Web of Science ®Google Scholar
• Legros S, Boxus M, Dewulf JF, Dequiedt F, Kettmann R, Twizere JC. Protein–protein interactions and gene expression regulation in HTLV-1 infected cells. Front. Biosci.14, 4138–4148 (2009).
   Google Scholar
• Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect. Dis.7(4), 266–281 (2007).
   PubMed Web of Science ®Google Scholar
• Calattini S, Chevalier SA, Duprez R et al. Discovery of a new human T-cell lymphotropic virus (HTLV-3) in central Africa. Retrovirology2, 30 (2005).
   PubMed Web of Science ®Google Scholar
• Calattini S, Chevalier SA, Duprez R et al. Human T-cell lymphotropic virus type 3: complete nucleotide sequence and characterization of the human tax3 protein. J. Virol.80(19), 9876–9888 (2006).
   PubMed Web of Science ®Google Scholar
• Calattini S, Betsem E, Froment A et al. Identification and complete sequence analysis of a new HTLV-3 strain from South Cameroon. AIDS Res. Hum. Retroviruses23(4), 596–596 (2007).
   Google Scholar
• Wolfe ND, Heneine W, Carr JK et al. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc. Natl Acad. Sci. USA102(22), 7994–7999 (2005).
   PubMed Web of Science ®Google Scholar
• Switzer WM, Qari SH, Wolfe ND, Burke DS, Folks TM, Heneine W. Ancient origin and molecular features of the novel human T-lymphotropic virus type 3 revealed by complete genome analysis. J. Virol.80(15), 7427–7438 (2006).
   PubMed Web of Science ®Google Scholar
• Switzer WM, Salemi M, Qari SH et al. Ancient, independent evolution and distinct molecular features of the novel human T-lymphotropic virus type 4. Retrovirology6, 9 (2009).
   PubMed Web of Science ®Google Scholar
• Mahieux R, Gessain A. The human HTLV-3 and HTLV-4 retroviruses: new members of the HTLV family. Pathol. Biol. (Paris)57(2), 161–166 (2009).
   PubMedGoogle Scholar
• Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl Acad. Sci. USA77(12), 7415–7419 (1980).
   PubMed Web of Science ®Google Scholar
• Kalyanaraman VS, Sarngadharan MG, Robertguroff M et al. A new subtype of human T-cell leukemia-virus (HTLV-LI) associated with a T-cell variant of hairy-cell leukemia. Science218(4572), 571–573 (1982).
   PubMed Web of Science ®Google Scholar
• Maeda N, Fan H, Yoshikai Y. Oncogenesis by retroviruses: old and new paradigms. Rev. Med. Virol.18(6), 387–405 (2008).
   PubMedGoogle Scholar
• Araujo A, Hall WW. Human T-lymphotropic virus type II and neurological disease. Ann. Neurol.56(1), 10–19 (2004).
   PubMed Web of Science ®Google Scholar
• Lowis GW, Sheremata WA, Minagar A. Epidemiologic features of HTLV-II: serologic and molecular evidence. Ann. Epidemiol.12(1), 46–66 (2002).
   PubMedGoogle Scholar
• Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC, Ruscetti FW. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat. Med.14(4), 429–436 (2008).
   PubMed Web of Science ®Google Scholar
• Macatonia SE, Cruickshank JK, Rudge P, Knight SC. Dendritic cells from patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation. AIDS Res. Hum. Retroviruses8(9), 1699–1706 (1992).
   PubMedGoogle Scholar
• Koyanagi Y, Itoyama Y, Nakamura N et al.In vivo infection of human T-cell leukemia virus type I in non-T cells. Virology196(1), 25–33 (1993).
   PubMed Web of Science ®Google Scholar
• Hanon E, Stinchcombe JC, Saito M et al. Fratricide among CD8(+) T lymphocytes naturally infected with human T cell lymphotropic virus type I. Immunity13(5), 657–664 (2000).
   PubMed Web of Science ®Google Scholar
• Hishizawa M, Imada K, Kitawaki T, Ueda M, Kadowaki N, Uchiyama T. Depletion and impaired interferon-α-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. Br. J. Haematol.125(5), 568–575 (2004).
   PubMedGoogle Scholar
• Asquith B, Mosley AJ, Barfield A et al. A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. J. Gen. Virol.86(Pt 5), 1515–1523 (2005).
   PubMedGoogle Scholar
• Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG. In vivo cellular tropism of human T-cell leukemia virus type 1. J. Virol.64(11), 5682–5687 (1990).
   PubMed Web of Science ®Google Scholar
• Tozser J, Weber IT. The protease of human T-cell leukemia virus type-1 is a potential therapeutic target. Curr. Pharm. Des.13(12), 1285–1294 (2007).
   PubMed Web of Science ®Google Scholar
• Boross P, Bagossi P, Weber IT, Tozser J. Drug targets in human T-lymphotropic virus type 1 (HTLV-1) infection. Infect. Disord. Drug Targets9(2), 159–171 (2009).
   PubMedGoogle Scholar
• Manel N, Battini JL, Taylor N, Sitbon M. HTLV-1 tropism and envelope receptor. Oncogene24(39), 6016–6025 (2005).
   PubMedGoogle Scholar
• Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell115(4), 449–459 (2003).
   PubMed Web of Science ®Google Scholar
• Manel N, Battini JL, Sitbon M. Human T cell leukemia virus envelope binding and virus entry are mediated by distinct domains of the glucose transporter GLUT1. J. Biol. Chem.280(32), 29025–29029 (2005).
   PubMedGoogle Scholar
• Jin Q, Agrawal L, VanHorn-Ali Z, Alkhatib G. Infection of CD4+ T lymphocytes by the human T cell leukemia virus type 1 is mediated by the glucose transporter GLUT-1: evidence using antibodies specific to the receptor’s large extracellular domain. Virology349(1), 184–196 (2006).
   PubMedGoogle Scholar
• Kinet S, Swainson L, Lavanya M et al. Isolated receptor binding domains of HTLV-1 and HTLV-2 envelopes bind Glut-1 on activated CD4+ and CD8+ T cells. Retrovirology4, 31 (2007).
   PubMedGoogle Scholar
• Takenouchi N, Jones KS, Lisinski I et al. GLUT1 is not the primary binding receptor but is associated with cell-to-cell transmission of human T-cell leukemia virus type 1. J. Virol.81(3), 1506–1510 (2007).
   PubMedGoogle Scholar
• Jones KS, Fugo K, Petrow-Sadowski C et al. Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells. J. Virol.80(17), 8291–8302 (2006).
   PubMedGoogle Scholar
• Jones KS, Huang YK, Chevalier SA et al. The receptor complex associated with human T-cell lymphotropic virus type 3 (HTLV-3) Env-mediated binding and entry is distinct from, but overlaps with, the receptor complexes of HTLV-1 and HTLV-2. J. Virol.83(10), 5244–5255 (2009).
   PubMedGoogle Scholar
• Pinon JD, Klasse PJ, Jassal SR et al. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J. Virol.77(18), 9922–9930 (2003).
   PubMedGoogle Scholar
• Jones KS, Petrow-Sadowski C, Bertolette DC, Huang Y, Ruscetti FW. Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. J. Virol.79(20), 12692–12702 (2005).
   PubMed Web of Science ®Google Scholar
• Lambert S, Bouttier M, Vassy R et al. HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165. Blood113(21), 5176–5185 (2009).
   PubMed Web of Science ®Google Scholar
• Ghez D, Lepelletier Y, Lambert S et al. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J. Virol.80(14), 6844–6854 (2006).
   PubMed Web of Science ®Google Scholar
• Sagara Y, Ishida C, Inoue Y, Shiraki H, Maeda Y. 71-kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human T-cell lymphotropic virus type 1. J. Virol.72(1), 535–541 (1998).
   PubMed Web of Science ®Google Scholar
• Jin Q, Agrawal L, Vanhorn-Ali Z, Alkhatib G. GLUT-1-independent infection of the glioblastoma/astroglioma U87 cells by the human T cell leukemia virus type 1. Virology353(1), 99–110 (2006).
   PubMedGoogle Scholar
• Boxus M, Twizere JC, Legros S, Dewulf JF, Kettmann R, Willems L. The HTLV-1 Tax interactome. Retrovirology5, 76 (2008).
   PubMedGoogle Scholar
• Kashanchi F, Brady JN. Transcriptional and post-transcriptional gene regulation of HTLV-1. Oncogene24(39), 5938–5951 (2005).
   PubMed Web of Science ®Google Scholar
• Lairmore MD, Silverman L, Ratner L. Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene24(39), 6005–6015 (2005).
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Sawa H, Lewis MJ et al. Thymus-derived leukemia-lymphoma in mice transgenic for the tax gene of human T-lymphotropic virus type I. Nat. Med.12(4), 466–472 (2006).
   PubMed Web of Science ®Google Scholar
• Younis I, Green PL. The human T-cell leukemia virus Rex protein. Front. Biosci.10, 431–445 (2005).
   PubMedGoogle Scholar
• Baydoun HH, Bellon M, Nicot C. HTLV-1 yin and yang: Rex and p30 master regulators of viral mRNA trafficking. AIDS Rev.10(4), 195–204 (2008).
   PubMedGoogle Scholar
• Ye J, Silverman L, Lairmore MD, Green PL. HTLV-1 Rex is required for viral spread and persistence in vivo but is dispensable for cellular immortalization in vitro. Blood102(12), 3963–3969 (2003).
   PubMedGoogle Scholar
• Nicot C, Harrod RL, Ciminale V, Franchini G. Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions. Oncogene24(39), 6026–6034 (2005).
   PubMed Web of Science ®Google Scholar
• Franchini G, Mulloy JC, Koralnik IJ et al. The human T-cell leukemia/lymphotropic virus type I p12I protein cooperates with the E5 oncoprotein of bovine papillomavirus in cell transformation and binds the 16-kilodalton subunit of the vacuolar H+ ATPase. J. Virol.67(12), 7701–7704 (1993).
   PubMed Web of Science ®Google Scholar
• Mulloy JC, Crownley RW, Fullen J, Leonard WJ, Franchini G. The human T-cell leukemia/lymphotropic virus type 1 p12I proteins bind the interleukin-2 receptor beta and gammac chains and affects their expression on the cell surface. J. Virol.70(6), 3599–3605 (1996).
   PubMedGoogle Scholar
• Johnson JM, Nicot C, Fullen J et al. Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein. J. Virol.75(13), 6086–6094 (2001).
   PubMedGoogle Scholar
• Ding W, Albrecht B, Luo R et al. Endoplasmic reticulum and cis-Golgi localization of human T-lymphotropic virus type 1 p12(I): association with calreticulin and calnexin. J. Virol.75(16), 7672–7682 (2001).
   PubMedGoogle Scholar
• Ding W, Albrecht B, Kelley RE et al. Human T-cell lymphotropic virus type 1 p12(I) expression increases cytoplasmic calcium to enhance the activation of nuclear factor of activated T cells. J. Virol.76(20), 10374–10382 (2002).
   PubMedGoogle Scholar
• Fukumoto R, Dundr M, Nicot C et al. Inhibition of T-cell receptor signal transduction and viral expression by the linker for activation of T cells-interacting p12(I) protein of human T-cell leukemia/lymphoma virus type 1. J. Virol.81(17), 9088–9099 (2007).
   PubMedGoogle Scholar
• Kim SJ, Nair AM, Fernandez S, Mathes L, Lairmore MD. Enhancement of LFA-1-mediated T cell adhesion by human T lymphotropic virus type 1 p12I1. J. Immunol.176(9), 5463–5470 (2006).
   PubMedGoogle Scholar
• Banerjee P, Feuer G, Barker E. Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells. J. Virol.81(18), 9707–9717 (2007).
   PubMed Web of Science ®Google Scholar
• Fukumoto R, Andresen V, Bialuk I et al.In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein. Blood113(16), 3726–3734 (2009).
   PubMedGoogle Scholar
• Bartoe JT, Albrecht B, Collins ND et al. Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo. J. Virol.74(3), 1094–1100 (2000).
   PubMedGoogle Scholar
• Collins ND, Newbound GC, Albrecht B, Beard JL, Ratner L, Lairmore MD. Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo. Blood91(12), 4701–4707 (1998).
   PubMed Web of Science ®Google Scholar
• Silverman LR, Phipps AJ, Montgomery A, Ratner L, Lairmore MD. Human T-cell lymphotropic virus type 1 open reading frame II-encoded p30II is required for in vivo replication: evidence of in vivo reversion. J. Virol.78(8), 3837–3845 (2004).
   PubMedGoogle Scholar
• Nicot C, Dundr M, Johnson JM et al. HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat. Med.10(2), 197–201 (2004).
   PubMedGoogle Scholar
• Younis I, Boris-Lawrie K, Green PL. Human T-cell leukemia virus open reading frame II encodes a posttranscriptional repressor that is recruited at the level of transcription. J. Virol.80(1), 181–191 (2006).
   PubMedGoogle Scholar
• Younis I, Khair L, Dundr M, Lairmore MD, Franchini G, Green PL. Repression of human T-cell leukemia virus type 1 and type 2 replication by a viral mRNA-encoded posttranscriptional regulator. J. Virol.78(20), 11077–11083 (2004).
   PubMedGoogle Scholar
• Yamamoto B, Li M, Kesic M, Younis I, Lairmore MD, Green PL. Human T-cell leukemia virus type 2 post-transcriptional control protein p28 is required for viral infectivity and persistence in vivo. Retrovirology5, 38 (2008).
   PubMedGoogle Scholar
• Zhang W, Nisbet JW, Albrecht B et al. Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300. J. Virol.75(20), 9885–9895 (2001).
   PubMedGoogle Scholar
• Lairmore MD, Albrecht B, D’Souza C et al.In vitro and in vivo functional analysis of human T cell lymphotropic virus type 1 pX open reading frames I and II. AIDS Res. Hum. Retroviruses16(16), 1757–1764 (2000).
   PubMedGoogle Scholar
• Zhang W, Nisbet JW, Bartoe JT, Ding W, Lairmore MD. Human T-lymphotropic virus type 1 p30(II) functions as a transcription factor and differentially modulates CREB-responsive promoters. J. Virol.74(23), 11270–11277 (2000).
   PubMedGoogle Scholar
• Awasthi S, Sharma A, Wong K et al. A human T-cell lymphotropic virus type 1 enhancer of Myc transforming potential stabilizes Myc-TIP60 transcriptional interactions. Mol. Cell. Biol.25(14), 6178–6198 (2005).
   PubMedGoogle Scholar
• Sinha-Datta U, Datta A, Ghorbel S, Dodon MD, Nicot C. Human T-cell lymphotrophic virus type I rex and p30 interactions govern the switch between virus latency and replication. J. Biol. Chem.282(19), 14608–14615 (2007).
   PubMedGoogle Scholar
• D’Agostino DM, Ranzato L, Arrigoni G et al. Mitochondrial alterations induced by the p13II protein of human T-cell leukemia virus type 1. Critical role of arginine residues. J. Biol. Chem.277(37), 34424–34433 (2002).
   PubMedGoogle Scholar
• Silic-Benussi M, Cannizzaro E, Venerando A et al. Modulation of mitochondrial K(+) permeability and reactive oxygen species production by the p13 protein of human T-cell leukemia virus type 1. Biochim. Biophys. Acta1787(7), 947–954 (2009).
   PubMedGoogle Scholar
• Silic-Benussi M, Cavallari I, Zorzan T et al. Suppression of tumor growth and cell proliferation by p13II, a mitochondrial protein of human T cell leukemia virus type 1. Proc. Natl Acad. Sci. USA101(17), 6629–6634 (2004).
   PubMedGoogle Scholar
• Hiraragi H, Michael B, Nair A, Silic-Benussi M, Ciminale V, Lairmore M. Human T-lymphotropic virus type 1 mitochondrion-localizing protein p13II sensitizes Jurkat T cells to Ras-mediated apoptosis. J. Virol.79(15), 9449–9457 (2005).
   PubMedGoogle Scholar
• Saggioro D, Barp S, Chieco-Bianchi L. Block of a mitochondrial-mediated apoptotic pathway in Tax-expressing murine fibroblasts. Exp. Cell Res.269(2), 245–255 (2001).
   PubMedGoogle Scholar
• Trevisan R, Daprai L, Acquasaliente L, Ciminale V, Chieco-Bianchi L, Saggioro D. Relevance of CREB phosphorylation in the anti-apoptotic function of human T-lymphotropic virus type 1 Tax protein in serum-deprived murine fibroblasts. Exp. Cell Res.299(1), 57–67 (2004).
   PubMed Web of Science ®Google Scholar
• Hiraragi H, Kim SJ, Phipps AJ et al. Human T-lymphotropic virus type 1 mitochondrion-localizing protein p13(II) is required for viral infectivity in vivo. J. Virol.80(7), 3469–3476 (2006).
   PubMedGoogle Scholar
• Boya P, Pauleau AL, Poncet D, Gonzalez-Polo RA, Zamzami N, Kroemer G. Viral proteins targeting mitochondria: controlling cell death. Biochim. Biophys. Acta1659(2–3), 178–189 (2004).
   PubMed Web of Science ®Google Scholar
• D’Agostino DM, Bernardi P, Chieco-Bianchi L, Ciminale V. Mitochondria as functional targets of proteins coded by human tumor viruses. Adv. Cancer Res.94, 87–142 (2005).
   PubMed Web of Science ®Google Scholar
• Matsuoka M, Green PL. The HBZ gene, a key player in HTLV-1 pathogenesis. Retrovirology6, 71 (2009).
   PubMedGoogle Scholar
• Arnold J, Yamamoto B, Li M et al. Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1. Blood107(10), 3976–3982 (2006).
   PubMed Web of Science ®Google Scholar
• Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, Devaux C, Mesnard JM. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J. Virol.76(24), 12813–12822 (2002).
   PubMed Web of Science ®Google Scholar
• Larocca D, Chao LA, Seto MH, Brunck TK. Human T-cell leukemia virus minus strand transcription in infected T-cells. Biochem. Biophys. Res. Commun.163(2), 1006–1013 (1989).
   PubMedGoogle Scholar
• Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer7(4), 270–280 (2007).
   PubMed Web of Science ®Google Scholar
• Murata K, Hayashibara T, Sugahara K et al. A novel alternative splicing isoform of human T-cell leukemia virus type 1 bZIP factor (HBZ-SI) targets distinct subnuclear localization. J. Virol.80(5), 2495–2505 (2006).
   PubMed Web of Science ®Google Scholar
• Nomura M, Ohashi T, Nishikawa K et al. Repression of tax expression is associated both with resistance of human T-cell leukemia virus type 1-infected T cells to killing by tax-specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model. J. Virol.78(8), 3827–3836 (2004).
   PubMedGoogle Scholar
• Lemasson I, Lewis MR, Polakowski N et al. Human T-cell leukemia virus type 1 (HTLV-1) bZIP protein interacts with the cellular transcription factor CREB to inhibit HTLV-1 transcription. J. Virol.81(4), 1543–1553 (2007).
   PubMed Web of Science ®Google Scholar
• Mesnard JM, Barbeau B, Devaux C. HBZ, a new important player in the mystery of adult T-cell leukemia. Blood108(13), 3979–3982 (2006).
   PubMedGoogle Scholar
• Matsumoto J, Ohshima T, Isono O, Shimotohno K. HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein. Oncogene24(6), 1001–1010 (2005).
   PubMed Web of Science ®Google Scholar
• Basbous J, Arpin C, Gaudray G, Piechaczyk M, Devaux C, Mesnard JM. The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J. Biol. Chem.278(44), 43620–43627 (2003).
   PubMedGoogle Scholar
• Thebault S, Basbous J, Hivin P, Devaux C, Mesnard JM. HBZ interacts with JunD and stimulates its transcriptional activity. FEBS Lett.562(1–3), 165–170 (2004).
   PubMedGoogle Scholar
• Hivin P, Basbous J, Raymond F et al. The HBZ-SP1 isoform of human T-cell leukemia virus type I represses JunB activity by sequestration into nuclear bodies. Retrovirology4, 14 (2007).
   PubMedGoogle Scholar
• Kuhlmann AS, Villaudy J, Gazzolo L, Castellazzi M, Mesnard JM, Dodon MD. HTLV-I HBZ cooperates with JunD to enhance transcription of the human telomerase reverse transcriptase gene (hTERT). Retrovirology4, 92 (2007).
   PubMedGoogle Scholar
• Mori N, Fujii M, Iwai K et al. Constitutive activation of transcription factor AP-1 in primary adult T-cell leukemia cells. Blood95(12), 3915–3921 (2000).
   PubMed Web of Science ®Google Scholar
• Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc. Natl Acad. Sci. USA103(3), 720–725 (2006).
   PubMed Web of Science ®Google Scholar
• Saito M, Matsuzaki T, Satou Y et al.In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology6, 19 (2009).
   PubMed Web of Science ®Google Scholar
• Liegeois F, Lafay B, Switzer WM et al. Identification and molecular characterization of new STLV-1 and STLV-3 strains in wild-caught nonhuman primates in Cameroon. Virology371(2), 405–417 (2008).
   PubMedGoogle Scholar
• Sintasath DM, Wolfe ND, Lebreton M et al. Simian T-lymphotropic virus diversity among nonhuman primates, Cameroon. Emerg. Infect. Dis.15(2), 175–184 (2009).
   PubMed Web of Science ®Google Scholar
• Van Dooren S, Meertens L, Lemey P, Gessain A, Vandamme AM. Full-genome analysis of a highly divergent simian T-cell lymphotropic virus type 1 strain in Macaca arctoides. J. Gen. Virol.86(Pt 7), 1953–1959 (2005).
   PubMed Web of Science ®Google Scholar
• Nerrienet E, Meertens L, Kfutwah A, Foupouapouognigni Y, Gessain A. Molecular epidemiology of simian T-lymphotropic virus (STLV) in wild-caught monkeys and apes from Cameroon: a new STLV-1, related to human T-lymphotropic virus subtype F, in a Cercocebus agilis. J. Gen. Virol.82(Pt 12), 2973–2977 (2001).
   PubMedGoogle Scholar
• Leendertz FH, Boesch C, Junglen S, Pauli G, Ellerbrok H. Characterization of a new simian T-lymphocyte virus type 1 (STLV-1) in a wild living chimpanzee (Pan troglodytes verus) from Ivory Coast: evidence of a new STLV-1 group? AIDS Res. Hum. Retroviruses19(3), 255–258 (2003).
   PubMedGoogle Scholar
• Calattini S, Betsem E, Bassot S et al. New strain of human T lymphotropic virus (HTLV) type 3 in a Pygmy from Cameroon with peculiar HTLV serologic results. J. Infect. Dis.199(4), 561–564 (2009).
   PubMedGoogle Scholar
• Besson G, Kazanji M. One-step, multiplex, real-time PCR assay with molecular beacon probes for simultaneous detection, differentiation, and quantification of human T-cell leukemia virus types 1, 2, and 3. J. Clin. Microbiol.47(4), 1129–1135 (2009).
   PubMedGoogle Scholar
• Duong YT, Jia H, Lust JA et al. Absence of evidence of HTLV-3 and HTLV-4 in patients with large granular lymphocyte (LGL) leukemia. AIDS Res. Hum. Retroviruses24(12), 1503–1505 (2008).
   PubMed Web of Science ®Google Scholar
• Endo K, Hirata A, Iwai K et al. Human T-cell leukemia virus type 2 (HTLV-2) Tax protein transforms a rat fibroblast cell line but less efficiently than HTLV-1 Tax. J. Virol.76(6), 2648–2653 (2002).
   PubMed Web of Science ®Google Scholar
• Chevalier SA, Meertens L, Pise-Masison C et al. The tax protein from the primate T-cell lymphotropic virus type 3 is expressed in vivo and is functionally related to HTLV-1 Tax rather than HTLV-2 Tax. Oncogene25(32), 4470–4482 (2006).
   PubMedGoogle Scholar
• Courgnaud V, Van Dooren S, Liegeois F et al. Simian T-cell leukemia virus (STLV) infection in wild primate populations in Cameroon: evidence for dual STLV type 1 and type 3 infection in agile mangabeys (Cercocebus agilis). J. Virol.78(9), 4700–4709 (2004).
   PubMed Web of Science ®Google Scholar
• Rousset R, Fabre S, Desbois C, Bantignies F, Jalinot P. The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins. Oncogene16(5), 643–654 (1998).
   PubMedGoogle Scholar
• Higuchi M, Tsubata C, Kondo R et al. Cooperation of NF-κB2/p100 activation and the PDZ domain binding motif signal in human T-cell leukemia virus type 1 (HTLV-1) Tax1 but not HTLV-2 Tax2 is crucial for interleukin-2-independent growth transformation of a T-cell line. J. Virol.81(21), 11900–11907 (2007).
   PubMedGoogle Scholar
• Tsubata C, Higuchi M, Takahashi M et al. PDZ domain-binding motif of human T-cell leukemia virus type 1 Tax oncoprotein is essential for the interleukin 2 independent growth induction of a T-cell line. Retrovirology2, 46 (2005).
   PubMedGoogle Scholar
• Xie L, Yamamoto B, Haoudi A, Semmes OJ, Green PL. PDZ binding motif of HTLV-1 Tax promotes virus-mediated T-cell proliferation in vitro and persistence in vivo. Blood107(5), 1980–1988 (2006).
   PubMedGoogle Scholar
• Halin M, Douceron E, Clerc I et al. Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classical bZIP domain but still inhibits Tax2-mediated transcription. Blood114(12), 2427–2438 (2009).
   PubMedGoogle Scholar
• Chevalier SA, Ko NL, Calattini S et al. Construction and characterization of a human T-cell lymphotropic virus type 3 infectious molecular clone. J. Virol.82(13), 6747–6752 (2008).
   PubMedGoogle Scholar
• Chevalier SA, Walic M, Calattini S et al. Construction and characterization of a full-length infectious simian T-cell lymphotropic virus type 3 molecular clone. J. Virol.81(12), 6276–6285 (2007).
   PubMed Web of Science ®Google Scholar
• Lieu YK, Kumar A, Pajerowski AG, Rogers TJ, Reddy EP. Requirement of c-Myb in T cell development and in mature T cell function. Proc. Natl Acad. Sci. USA101(41), 14853–14858 (2004).
   PubMedGoogle Scholar
• Eklund EA. The role of HOX genes in malignant myeloid disease. Curr. Opin. Hematol.14(2), 85–89 (2007).
   PubMed Web of Science ®Google Scholar
• Eklund EA. The role of HOX genes in myeloid leukemogenesis. Curr. Opin. Hematol.13(2), 67–73 (2006).
   PubMedGoogle Scholar
• Kim FJ, Manel N, Garrido EN, Valle C, Sitbon M, Battini JL. HTLV-1 and -2 envelope SU subdomains and critical determinants in receptor binding. Retrovirology1, 41 (2004).
   PubMedGoogle Scholar
• Slattery JP, Franchini G, Gessain A. Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses. Genome Res.9(6), 525–540 (1999).
   PubMed Web of Science ®Google Scholar
• Antia R, Regoes RR, Koella JC, Bergstrom CT. The role of evolution in the emergence of infectious diseases. Nature426(6967), 658–661 (2003).
   PubMed Web of Science ®Google Scholar
• Wolfe ND, Prosser TA, Carr JK et al. Exposure to nonhuman primates in rural Cameroon. Emerg. Infect. Dis.10(12), 2094–2099 (2004).
   PubMed Web of Science ®Google Scholar
• Wolfe ND, Switzer WM, Carr JK et al. Naturally acquired simian retrovirus infections in central African hunters. Lancet363(9413), 932–937 (2004).
   PubMed Web of Science ®Google Scholar
• Wolfe ND, Daszak P, Kilpatrick AM, Burke DS. Bushmeat hunting, deforestation, and prediction of zoonoses emergence. Emerg. Infect. Dis.11(12), 1822–1827 (2005).
   PubMed Web of Science ®Google Scholar
• Martinez-Cajas JL, Wainberg MA. Antiretroviral therapy – optimal sequencing of therapy to avoid resistance. Drugs68(1), 43–72 (2008).
   PubMedGoogle Scholar
• Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J. Virol.69(5), 2863–2868 (1995).
   PubMed Web of Science ®Google Scholar
• Igakura T, Stinchcombe JC, Goon PKC et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science299(5613), 1713–1716 (2003).
   PubMed Web of Science ®Google Scholar
• Jolly C, Sattentau QJ. Retroviral spread by induction of virological synapses. Traffic5(9), 643–650 (2004).
   PubMed Web of Science ®Google Scholar
• Majorovits E, Nejmeddine M, Tanaka Y, Taylor GP, Fuller SD, Bangham CR. Human T-lymphotropic virus-1 visualized at the virological synapse by electron tomography. PLoS One3(5), e2251 (2008).
   Google Scholar
• Oh U, Jacobson S. Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy. Neurol. Clin.26(3), 781–797, ix–x (2008).
   PubMed Web of Science ®Google Scholar
• Nakamura T. HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy. Folia Neuropathol.47(2), 182–194 (2009).
   PubMedGoogle Scholar
• Tsukasaki K, Hermine O, Bazarbachi A et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J. Clin. Oncol.27(3), 453–459 (2009).
   PubMed Web of Science ®Google Scholar
• Kchour G, Tarhini M, Kooshyar MM et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood113(26), 6528–6532 (2009).
   PubMed Web of Science ®Google Scholar
• Garcia-Lerma JG, Nidtha S, Heneine W. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine. J. Infect. Dis.184(4), 507–510 (2001).
   PubMedGoogle Scholar
• Hill SA, Lloyd PA, McDonald S, Wykoff J, Derse D. Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. J. Infect. Dis.188(3), 424–427 (2003).
   PubMed Web of Science ®Google Scholar
• Murakami J, Nagai N, Shigemasa K, Ohama K. Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur. J. Cancer35(6), 1027–1034 (1999).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Takahashi H, Jinmei H, Takayama Y, Saneyoshi M. Inhibition of vertebrate telomerases by the triphosphate derivatives of some biologically active nucleosides. Nucleosides Nucleotides Nucleic Acids22(5–8), 1575–1577 (2003).
   PubMed Web of Science ®Google Scholar
• Falchetti A, Franchi A, Bordi C et al. Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J. Bone Miner. Res.20(3), 410–418 (2005).
   PubMed Web of Science ®Google Scholar
• Hara T, Matsumura-Arioka Y, Ohtani K, Nakamura M. Role of human T-cell leukemia virus type I Tax in expression of the human telomerase reverse transcriptase (hTERT) gene in human T-cells. Cancer Science99(6), 1155–1163 (2008).
   PubMedGoogle Scholar
• Bellon M, Nicot C. Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells. Blood112(7), 2946–2955 (2008).
   PubMedGoogle Scholar
• Bellon M, Nicot C. Telomerase: a crucial player in HTLV-I-induced human T-cell leukemia. Cancer Genomics Proteomics4(1), 21–25 (2007).
   PubMedGoogle Scholar
• Feng X, Heyden NV, Ratner L. a interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts. J. Virol.77(24), 13389–13395 (2003).
   PubMed Web of Science ®Google Scholar
• Feng X, Ratner L. Human T-cell leukemia virus type 1 blunts signaling by interferon alpha. Virology374(1), 210–216 (2008).
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, El-Sabban ME, Nasr R et al. Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood93(1), 278–283 (1999).
   PubMed Web of Science ®Google Scholar
• El-Sabban ME, Nasr R, Dbaibo G et al. Arsenic-interferon-α-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-k B activation. Blood96(8), 2849–2855 (2000).
   PubMed Web of Science ®Google Scholar
• Nasr R, Rosenwald A, El-Sabban ME et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood101(11), 4576–4582 (2003).
   PubMed Web of Science ®Google Scholar
• Chiacchio U, Balestrieri E, Macchi B et al. Synthesis of phosphonated carbocyclic 2´-oxa-3´-aza-nucleosides: novel inhibitors of reverse transcriptase. J. Med. Chem.48(5), 1389–1394 (2005).
   PubMed Web of Science ®Google Scholar
• Chiacchio U, Rescifina A, Iannazzo D et al. Phosphonated carbocyclic 2´-oxa-3´-azanucleosides as new antiretroviral agents. J. Med. Chem.50(15), 3747–3750 (2007).
   PubMedGoogle Scholar
• Balestrieri E, Matteucci C, Ascolani A et al. Effect of phosphonated carbocyclic 2´-oxa-3´-aza-nucleoside on human T-cell leukemia virus type 1 infection in vitro. Antimicrob. Agents Chemother.52(1), 54–64 (2008).
   PubMed Web of Science ®Google Scholar
• Tozser J, Oroszlan S. Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Curr. Pharm. Des.9(22), 1803–1815 (2003).
   PubMedGoogle Scholar
• Li M, Laco GS, Jaskolski M et al. Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design. Proc. Natl Acad. Sci. USA102(51), 18332–18337 (2005).
   PubMed Web of Science ®Google Scholar
• Pettit SC, Sanchez R, Smith T, Wehbie R, Derse D, Swanstrom R. HIV type 1 protease inhibitors fail to inhibit HTLV-I Gag processing in infected cells. AIDS Res. Hum. Retroviruses14(11), 1007–1014 (1998).
   PubMedGoogle Scholar
• Bagossi P, Kadas J, Miklossy G, Boross P, Weber IT, Tozser J. Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. J. Virol. Methods119(2), 87–93 (2004).
   PubMedGoogle Scholar
• Nguyen JT, Zhang M, Kumada HO et al. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors. Bioorg. Med. Chem. Lett.18(1), 366–370 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang M, Nguyen JT, Kumada HO et al. Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme. Bioorg. Med. Chem.16(14), 6880–6890 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang M, Nguyen JT, Kumada HO et al. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties. Bioorg. Med. Chem.16(10), 5795–5802 (2008).
   PubMed Web of Science ®Google Scholar
• Kadas J, Weber IT, Bagossi P et al. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell leukemia virus type 1 protease. J. Biol. Chem.279(26), 27148–27157 (2004).
   PubMedGoogle Scholar
• Feher A, Weber IT, Bagossi P et al. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur. J. Biochem.269(16), 4114–4120 (2002).
   PubMedGoogle Scholar
• Rabaaoui S, Zouhiri F, Lancon A, Leh H, d’Angelo J, Wattel E. Inhibitors of strand transfer that prevent integration and inhibit human T-cell leukemia virus type 1 early replication. Antimicrob. Agents Chemother.52(10), 3532–3541 (2008).
   PubMedGoogle Scholar
• Grobler JA, Stillmock K, Hu B et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl Acad. Sci. USA99(10), 6661–6666 (2002).
   PubMed Web of Science ®Google Scholar
• Semenova EA, Johnson AA, Marchand C, Pommier Y. Integration of human immunodeficiency virus as a target for antiretroviral therapy. Curr. Opin. HIV AIDS1(5), 380–387 (2006).
   PubMedGoogle Scholar
• Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov.4(3), 236–248 (2005).
   PubMed Web of Science ®Google Scholar
• Snasel J, Krejcik Z, Jencova V et al. Integrase of Mason-Pfizer monkey virus. FEBS J.272(1), 203–216 (2005).
   PubMedGoogle Scholar
• Kobe B, Center RJ, Kemp BE, Poumbourios P. Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc. Natl Acad. Sci. USA96(8), 4319–4324 (1999).
   PubMed Web of Science ®Google Scholar
• Pinon JD, Kelly SM, Price NC, Flanagan JU, Brighty DW. An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein. J. Virol.77(5), 3281–3290 (2003).
   PubMedGoogle Scholar
• Mirsaliotis A, Lamb D, Brighty DW. Nonhelical leash and α-helical structures determine the potency of a peptide antagonist of human T-cell leukemia virus entry. J. Virol.82(10), 4965–4973 (2008).
   PubMedGoogle Scholar
• Lamb D, Mirsaliotis A, Kelly SM, Brighty DW. Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry. J. Biol. Chem.284(10), 6575–6584 (2009).
   PubMedGoogle Scholar
• Yasunaga J, Matsuoka M. Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms. Cancer Control14(2), 133–140 (2007).
   PubMedGoogle Scholar
• Takeda S, Maeda M, Morikawa S et al. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int. J. Cancer109(4), 559–567 (2004).
   PubMed Web of Science ®Google Scholar
• Maeda N, Kawamura T, Hoshino H et al. Inhibition of human T-cell leukemia virus type 1 replication by antisense env oligodeoxynucleotide. Biochem. Biophys. Res. Commun.243(1), 109–112 (1998).
   PubMedGoogle Scholar
• Akimoto M, Kozako T, Sawada T et al. Anti-HTLV-1 Tax antibody and Tax-specific cytotoxic T lymphocyte are associated with a reduction in HTLV-1 proviral load in asymptomatic carriers. J. Med. Virol.79(7), 977–986 (2007).
   PubMed Web of Science ®Google Scholar
• Ozaki A, Arima N, Matsushita K et al. Cyclosporin A inhibits HTLV-I tax expression and shows anti-tumor effects in combination with VP-16. J. Med. Virol.79(12), 1906–1913 (2007).
   PubMedGoogle Scholar
• Clamp M, Cuff J, Searle SM, Barton GJ. The Jalview Java alignment editor. Bioinformatics20(3), 426–427 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight choice. Nucleic Acids Res.22(22), 4673–4680 (1994).
   PubMed Web of Science ®Google Scholar